Citations

Mayo Clinic

Showing 10 of 108599 citations.

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Fa’ak, Faisal , Buni, Maryam, Falohun, Adewunmi, Song, Juhee , Trinh, Van Anh, Tahon, Nourel Hoda , Elsayes, Khaled M. , Ludford, Kaysia , Montazari, Emma J., Chernis, Julia , Dimitrova, Maya , Sandigursky, Sabina, Sparks, Jeffrey A. , Abu-Shawer, Osama , Rahma, Osama E. , Thanarajasingam, Uma , Zeman, Ashley M., Talukder, Rafee , Chung, Sarah H. , Grivas, Petros , Daher, May , Abudayyeh, Ala , Osman, Iman , Suarez‐Almazor, María E. , Abdel‐Wahab, Noha , Diab, Adi , Grivas, Petros , Weber, Jeffrey , Diab, Adi , Sparks, Jeffrey A , Lu, Huifang , Johnson, Daniel Hartman , Zobniw, Chrystia M. , Awiwi, Muhammad O. , Singh, Namrata , Weber, Jeffrey S. , Tayar, Jean H.

Journal for ImmunoTherapy of Cancer | June 16, 2023 | Volume: 11 | Issue: 6 | Pages: e006814

10.1136/jitc-2023-006814 | PMID 37328287 Get It

Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 receptor (anti-IL-6R) as therapy for irAEs. Methods We performed a retrospective multicenter study evaluating patients diagnosed with de novo irAEs or flare of pre-existing autoimmune disease following ICI and were treated with anti-IL-6R. Our objectives were to assess the improvement of irAEs as well as the overall tumor response rate (ORR) before and after anti-IL-6R treatment. Results We identified a total of 92 patients who received therapeutic anti-IL-6R antibodies (tocilizumab or sarilumab). Median age was 61 years, 63% were men, 69% received anti-programmed cell death protein-1 (PD-1) antibodies alone, and 26% patients were treated with the combination of anti-cytotoxic T lymphocyte antigen-4 and anti-PD-1 antibodies. Cancer types were primarily melanoma (46%), genitourinary cancer (35%), and lung cancer (8%). Indications for using anti-IL-6R antibodies included inflammatory arthritis (73%), hepatitis/cholangitis (7%), myositis/myocarditis/myasthenia gravis (5%), polymyalgia rheumatica (4%), and one patient each with autoimmune scleroderma, nephritis, colitis, pneumonitis and central nervous system vasculitis. Notably, 88% of patients had received corticosteroids, and 36% received other disease-modifying antirheumatic drugs (DMARDs) as first-line therapies, but without adequate improvement. After initiation of anti-IL-6R (as first-line or post-corticosteroids and DMARDs), 73% of patients showed resolution or change to ≤grade 1 of irAEs after a median of 2.0 months from initiation of anti-IL-6R therapy. Six patients (7%) stopped anti-IL-6R due to adverse events. Of 70 evaluable patients by RECIST (Response Evaluation Criteria in Solid Tumors) V.1.1 criteria; the ORR was 66% prior versus 66% after anti-IL-6R (95% CI, 54% to 77%), with 8% higher complete response rate. Of 34 evaluable patients with melanoma, the ORR was 56% prior and increased to 68% after anti-IL-6R (p=0.04). Conclusion Targeting IL-6R could be an effective approach to treat several irAE types without hindering antitumor immunity. This study supports ongoing clinical trials evaluating the safety and efficacy of tocilizumab (anti-IL-6R antibody) in combination with ICIs ( NCT04940299 , NCT03999749 ).
Health Disparities in Radiation Oncology: Our Call to Action
Chaurasia, Avinash , LeCompte, M.C. , Franco, Idalid , Garda, Allison E. , Pereira, Ian , Bhatia, Rohini K. , Taparra, Kekoa , Li, Benjamin

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: 6-8

10.37549/aro1262 Get It

Environmentally Sustainable Radiation Oncology: Can We Turn the Tides?
Anderson, Justin D. , McComas, Kyra N. , Tam, Andrew , Bloom, Julie R. , Lichter, Katie E.

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: 46-47

10.37549/aro1320 Get It

Analysis of the Radiation Oncology In-Training Examination Content Using a Clinical Care Path Conceptual Framework
Rogacki, Kevin , Jeans, Elizabeth B. , Gutiontov, Stanley I. , Goodman, Chelain R. , Golden, Daniel William

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.37549/aro1287 Get It

Radiotherapeutic Management of Oligometastatic Disease in Low- and Middle-Income Countries: The Current State of Affairs and Perspectives on Future Implementation
Jia, Angela Y. , Deek, Matthew P. , Phillips, Ryan

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: 11-15

10.37549/aro1245 Get It

Pro-Con Debate: Role of Methadone in Enhanced Recovery After Surgery Protocols—Superior Analgesic or Harmful Drug?
D’Souza, Ryan S. , Esfahani, Kamilla , Dunn, Lauren K. , D'Souza, Ryan S

Anesthesia & Analgesia | June 16, 2023 | Volume: 137 | Issue: 1 | Pages: 76-82

10.1213/ane.0000000000006331 | PMID 37326866 Get It

Enhanced recovery after surgery (ERAS) protocols are standardized and designed to provide superior analgesia, reduce opioid consumption, improve patient recovery, and reduce hospital length of stay. Yet, moderate-to-severe postsurgical pain continues to afflict over 40% of patients and remains a major priority for anesthesia research. Methadone administration in the perioperative setting may reduce postoperative pain scores and have opioid-sparing effects, which may be beneficial for enhanced recovery. Methadone possesses a multimodal profile consisting of µ-opioid agonism, N -methyl-d-aspartate (NMDA) receptor antagonism, and reuptake inhibition of serotonin and norepinephrine. Furthermore, it may attenuate the development of chronic postsurgical pain. However, caution is advised with perioperative use of methadone in specific high-risk patient populations and surgical settings. Methadone’s wide pharmacokinetic variability, opioid-related adverse effects, and potential negative impact on cost-effectiveness may also limit its use in the perioperative setting. In this PRO-CON commentary article, the authors debate whether methadone should be incorporated in ERAS protocols to provide superior analgesia with no increased risks.
Management of epilepsy with eyelid myoclonia: Results of an international expert consensus panel
Smith, Kelsey M. , Wirrell, Elaine , Choi, Hyunmi , Trenité, Dorothée Kasteleijn‐Nolst, Jones, Hannah , Knupp, Kelly G. , Mugar, Jon, Nordli, Douglas R. , Riva, Antonella , Striano, Pasquale, Thiele, Elizabeth A. , Zawar, Ifrah , Wirrell, Elaine C , Choi, Hyunmi , Kasteleijn-Nolst Trenité, Dorothée , Knupp, Kelly G , Riva, Antonella , Stern, John M , Striano, Pasquale , Thiele, Elizabeth A , Zawar, Ifrah , Smith, Kelsey M , Andrade, Danielle M. , Stern, John M.

Epilepsia | June 16, 2023 | Volume: 64 | Issue: 9 | Pages: 2342-2350

10.1111/epi.17682 | PMID 37326215 Get It

AbstractObjectiveThere are limited data about the treatment and management of epilepsy with eyelid myoclonia (EEM). The objective of this study was to determine areas of consensus among an international panel of experts for the management of EEM (formerly known as Jeavons syndrome).MethodsAn international steering committee was convened of physicians and patients/caregivers with expertise in EEM. This committee summarized the current literature and identified an international panel of experts (comprising 25 physicians and five patients/caregivers). This panel participated in a modified Delphi process, including three rounds of surveys to determine areas of consensus for the treatment, other areas of management, and prognosis for EEM.ResultsThere was a strong consensus for valproic acid as the first‐line treatment, with levetiracetam or lamotrigine as preferable alternatives for women of childbearing age. There was a moderate consensus that ethosuximide and clobazam are also efficacious. There was a strong consensus to avoid sodium channel‐blocking medications, except for lamotrigine, as they may worsen seizure control. There was consensus that seizures typically persist into adulthood, with remission occurring in <50% of patients. There was less agreement about other areas of management, including dietary therapy, lens therapy, candidacy for driving, and outcome.SignificanceThis international expert panel identified multiple areas of consensus regarding the optimal management of EEM. These areas of consensus may inform clinical practice to improve the management of EEM. In addition, multiple areas with less agreement were identified, which highlight topics for further research.
A 10-Year Glance at the Global Health Scholars Program
Lee, Becky K., Gaines, Dakim, MacDuffie, Emily , Anderson, Justin D.

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: 40-40

10.37549/aro1315 Get It

Medical School Curricula: Giving Radiation Oncology a Seat at the Table
Chaurasia, Avinash , Price, Jeremy , Jeans, Elizabeth B. , Dooley, Sarah A.

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: 4-4

10.37549/aro1278 Get It

Measured Distribution of Total Red Bone Marrow in Young Children
Abu‐Gheida, Ibrahim , Zaghal, Arwa , Naffaa, Lena , Taddei, P

Applied Radiation Oncology | June 16, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.37549/aro1273 Get It